Lopedote P, Shouse G, Puverel S, Muir A, et al. A chemotherapy-free regimen of acalabrutinib, umbralisib and ublituximab achieved high response rates and undetectable minimal residual disease in patients with untreated mantle cell lymphoma. Br J Haematol 2025 Apr 2. doi: 10.1111/bjh.20041.
PMID: 40176303